NeoGenomics is trading 4.12% up at $19.72, moving alongside a broader September 17, 2026 equity rally.
- The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are all higher, supporting risk appetite after the Federal Reserve’s September 16 rate decision.
- Recent Morgan Stanley conference commentary highlighted strong NGS growth and reimbursement opportunities, but no new company-specific catalyst directly explains today’s move.